Use of convalescent plasma in patients with coronavirus disease (Covid-19): Systematic review and meta-analysis


Correspondence. Fernando Tortosa fernandotortosa@gmail.com +5492944357104 Moreno 601 SanCarlos de Bariloche, Rio Negro, Argentina CP 8400

All authors declare that they have no conflicts of interest.

We do not have external sources of financing: this study was carried out thanks to the support of the Ministry of Health of the province of Rio Negro.

Contribution of the authors

<table>
<thead>
<tr>
<th>FULL NAME (INITIALS)</th>
<th>Conceptualization</th>
<th>Methodology</th>
<th>Software</th>
<th>Validation</th>
<th>Formal analysis</th>
<th>Investigation</th>
<th>Resources</th>
<th>Data curation</th>
<th>Writing (original draft preparation)</th>
<th>Reviewing</th>
<th>Editing</th>
<th>Supervision</th>
<th>Project administration</th>
<th>Funding acquisition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fernando Tortosa</td>
<td>X</td>
<td>X</td>
<td>n/a</td>
<td>X</td>
<td>X</td>
<td>n/a</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td>n/a</td>
</tr>
</tbody>
</table>
Abstract

Objectives
To assess the effects of convalescent plasma treatment in patients with coronavirus disease (COVID-19).

Study design
Systematic review and Meta-analysis

Data sources
A systematic search was carried out on the L · OVE (Living OVerview of Evidence) platform for COVID-19 until October 31, 2020

Study selection
Randomized clinical trials in which people with probable or confirmed COVID-19 were randomized to drug treatment, standard care, or placebo. Pairs of reviewers independently screened potentially eligible articles.

Methods
The PRISMA guidelines were followed for conducting a systematic review and meta-analysis. The risk of bias of the included studies was assessed using the Cochrane risk of bias tool 2.0, and the certainty of the evidence using the recommendation assessment, development and evaluation (GRADE) approach. For each outcome, the interventions were classified into groups, from most to least beneficial or harmful.
Results

We identified 10 RCTs (randomized controlled trials) involving 11,854 patients in which convalescent plasma was compared with standard of care or other treatments. The results of five RCTs that evaluated the use of convalescent plasma in patients with COVID-19 did not show significant differences in the effect on mortality and the need for invasive mechanical ventilation.

Conclusions

Current evidence is insufficient to recommend the use of convalescent plasma in the treatment of moderate or severe COVID-19.

Key words (MeSH): "convalescent plasma", "plasma", "Coronavirus infections", "COVID-19"

Keywords (MeSH): "COVID-19"[Mesh], "SARS-CoV-2"[Mesh], "COVID-19 drug treatment"[Supplementary Concept], "COVID-19 serotherapy"[Supplementary Concept], "Plasma"[Mesh]

Introduction

Patients who have recovered from infectious diseases have antibodies in their blood that protect them from future diseases caused by the same infectious agent. These antibodies can be obtained from blood plasma, which in this context is called convalescent plasma.

The transfusion of convalescent plasma to a person with a viral infection could neutralize the pathogenic microorganism that affects them and, thus, give that person time to initiate an active immune response, that is, generated by their own immune system.

Some believe that this therapy played a fundamental role at a time when we did not have effective vaccines or medications for most diseases. The antecedent of successful use in our country arises from the treatment of Argentine Hemorrhagic Fever [1] [2]. As we are in precisely that situation today in the face of COVID-19, interest in using it has resurfaced. But if we had an efficient vaccine or drug today, the option of using convalescent plasma would probably not be considered to use convalescent plasma, because there are practical difficulties in obtaining it and its availability, consequently, is limited [3]. The central thing to consider could be an alternative for the treatment of COVID-19, while scientists discover a better option, however, the certainty that it could work in other situations is also very low.

We conducted a systematic review to summarize the available evidence regarding the use of convalescent plasma in patients with coronavirus disease (COVID-19).
Methods

This study was conducted following the PRISMA guidelines (prefered reported items in systematic reviews and meta-analysis) for conducting and publishing systematic reviews [4]. The protocol was registered in PROSPERO with registration number CRD42020226735 "Use of convalescent plasma in patients with coronavirus disease (Covid-19): systematic review and meta-analysis".

objective

To assess the effects of convalescent plasma treatment in patients with coronavirus disease (COVID-19) compared to standard treatment or placebo.

Clinical question

In people with coronavirus disease (COVID-19), should convalescent plasma be used compared to standard treatment alone?

PICO question

Population People with coronavirus disease (COVID-19)

Intervention Convalescent plasma plus standard treatment

Comparison Standard Treatment or Placebo

Outcomes Mortality, admission to AVM (mechanical ventilatory assistance), serious adverse events, length of hospitalization, time of mechanical ventilation, length of stay in the ICU (Intensive Care Unit)

Design

Systematic review and meta-analysis

Data sources

Systematic searches were carried out on the L · OVE (Living OVerview of Evidence) platform for COVID-19, a system that maps PICO questions to a repository developed by the Epistemonikos Foundation, this repository is continuously updated by searching electronic databases, server pre-printing, test logs and other resources relevant to COVID-19. The electronic databases PubMed, LiLacs, Cochrane Library and the clinicaltrials.gov register of clinical trials were also searched in duplicate. For more information see Supplementary Information Annex.

No search restrictions were imposed on electronic databases. The last search date was carried out on November 1, 2020.

Study selection
Randomized controlled trials (RCTs) were selected for this therapeutic pharmacological intervention (without age restriction) with confirmed COVID-19 and trials comparing this intervention head-to-head or with no intervention or placebo, providing evidence on critical or important outcomes, were included. (mortality, mechanical ventilation, symptoms resolution or clinical improvement, and serious adverse events).

Two review authors independently screened all titles and abstracts, followed by the full texts of the trials that were identified as potentially eligible. A third reviewer resolved the conflicts.

**Data collection**

For each eligible trial, pairs of reviewers independently extracted data using a data extraction form.

Reviewers collected information on trial characteristics (trial registration, publication status, study status, design), participant characteristics, and outcomes of interest. The reviewers resolved discrepancies by discussion and, where necessary, with the intervention of a third reviewer.

**Risk of bias of included studies**

An assessment of risk of bias was applied to RCTs based on randomization, allocation, concealment, blinding or other biases relevant to sources of risk of bias. For each eligible trial and outcome, the reviewers used a review using the Cochrane Risk of Bias in RCTs (RoB 2.0) [5] to rate trials in the following domains: bias arising from the randomisation process; bias due to deviations from the planned intervention; bias due to missing outcome data; bias in the measurement of the outcome; bias in the selection of outcome reports (including deviations from the recorded protocol) and bias arising from early termination for the benefit of the intervention. Trials were rated at high risk of bias overall if one or more domains were rated as 'Some concerns or likely high risk of bias' or as 'high risk of bias', and as low risk of bias overall, if all domains were rated as "some concerns, probably low risk of bias". The reviewers resolved discrepancies by discussion and when not possible they were resolved by a third party.

**Effect measures and statistical analysis**

We summarize the effect of interventions on dichotomous outcomes using relative risks (RR) and corresponding 95% confidence intervals (CI).

For any meta-analytic pooling, whenever the data allowed, all studies were pooled. The relative effect was calculated through a relative risk meta-analysis using the Mantel and Haenszel method with a random effect model. The absolute effect was estimated from the relative risk and the risk observed in control groups of the included studies. We performed meta-analysis of direct comparisons and the rest of the calculations using the "meta" package in RStudio Version 1.3.1093.14. [6]
To assess the absolute effects of the interventions, related effects applied to baseline risks (risks without intervention), mortality and baseline risks of mechanical ventilation were extracted from the ISARIC cohort (https://isaric.tghn.org/) and for adverse events and the resolution and/or improvement of symptoms, we used the risk observed in the control or standard treatment groups of the included RCTs. [7]

Certainty of the evidence

We assessed the certainty of the evidence by grading the recommendations assessment, development approach and assessment (GRADE) [8]. Two methodologists experienced in using GRADE scored each domain for each comparison separately and resolved discrepancies by consensus. We rated the certainty for each comparison and outcome as high, moderate, low, or very low, based on considerations of risk of bias, inconsistency, indirect, publication bias, and imprecision.

Sensitivity, subgroup and publication bias analysis

The risk of bias according to current standards for pharmacological interventions in COVID-19 and the quality of the infused plasma were considered as potential subgroup effects or effect modifiers, based on the concentration of neutralizing antibodies required in the standards set in the clinical trials.

The presence of publication bias was analyzed by performing a funnel plot and using the Eggers test statistic [9].

Sample power

A sample size calculation was performed to determine whether the total number of patients included in the meta-analysis was less than the required number of patients to achieve sample power and to determine if the optimal information size (TOI) was met for a power 80%. (d = 0.10, RR, k = 6, n1 = 500, n2 = 500, p = 0.05, heterogeneity = "moderate") [10].

Results

Five RCTs [11] [12] [13] [14] [15] were identified that included 734 patients in which convalescent plasma was compared with standard treatment or other treatments.
The characteristics of the included studies can be seen in Table 1. Agarwal et al conducted the largest study to date that included 235 patients in the intervention arm and 229 in control.

All studies included severe and moderate patients. Mortality in the control arms ranged from 10% to 25.6%. Convalescent plasma was administered in one or two infusions to symptomatic patients in all cases. The risk of bias of the studies was low overall for death or admission to AVM and high for the rest of the outcomes. This was due to problems in randomization and blinding in most studies, the presence of multiple co-interventions and the reporting of results. See Chart 2 for risk of bias.

Graph 2. Risk of bias of the included studies

<table>
<thead>
<tr>
<th>Study</th>
<th>D1</th>
<th>D2</th>
<th>D3</th>
<th>D4</th>
<th>D5</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poonawala 2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lui 2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gao 2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wu et al 2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liu et al 2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guo et al 2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yang et al 2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shastry et al 2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suryawansa et al 2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Domains:
- D1: Bias due to randomisation
- D2: Bias due to deviations from intended intervention
- D3: Bias due to missing data
- D4: Bias due to outcome measurement
- D5: Bias due to selection of reported result

Judgement:
- High
- Some concerns
- Low
With 10 studies included and more than 5000 patients per branch, 100% of the sample power was reached with optimal information size determination (TOI).

Outcome mortality

The use of convalescent plasma has no impact on mortality of patients interned with COVID-19, RR 1.02 (95% CI: 0.94 to 1.12); RD 0.2% more (0.6 minus 1 more); HIGH Certainty ⨁⨁ ⨁⨁ ⨁. See Chart 3 and 3a Forest plot.

Chart 3 Forest plot. Effect of convalescent plasma use, Outcome: Mortality at 30 days, Randomized controlled studies. Chart 3a Forest plot subgroup effects: Studies with high risk of bias vs low risk of bias.

<table>
<thead>
<tr>
<th>Study</th>
<th>Experimental Events Total</th>
<th>Control Events Total</th>
<th>Risk Ratio</th>
<th>RR 95% CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma AR 2020</td>
<td>25 228</td>
<td>12 105</td>
<td>0.90</td>
<td>[0.80, 1.00]</td>
<td>15%</td>
</tr>
<tr>
<td>Li Ly col 2020</td>
<td>8 51</td>
<td>12 50</td>
<td>0.05</td>
<td>[0.29, 1.46]</td>
<td>10%</td>
</tr>
<tr>
<td>CONCOVID 2020</td>
<td>6 43</td>
<td>11 43</td>
<td>0.05</td>
<td>[0.22, 1.34]</td>
<td>0.8%</td>
</tr>
<tr>
<td>ConvPAS 2020</td>
<td>0 38</td>
<td>4 43</td>
<td>0.03</td>
<td>[0.06, 1.44]</td>
<td>0.9%</td>
</tr>
<tr>
<td>Placid-Trial 2020</td>
<td>31 229</td>
<td>34 235</td>
<td>0.94</td>
<td>[0.80, 1.17]</td>
<td>3.0%</td>
</tr>
<tr>
<td>Libster y col (INFANT) 2021</td>
<td>2 80</td>
<td>4 40</td>
<td>0.50</td>
<td>[0.29, 0.93]</td>
<td>0.2%</td>
</tr>
<tr>
<td>ILBS 02 COVID-19 2020</td>
<td>14 14</td>
<td>15 15</td>
<td>1.04</td>
<td>[0.90, 1.13]</td>
<td>91.9%</td>
</tr>
<tr>
<td>PICP 19 Ray y col 2020</td>
<td>10 40</td>
<td>14 40</td>
<td>0.71</td>
<td>[0.53, 0.94]</td>
<td>1.3%</td>
</tr>
<tr>
<td><strong>Random effects model</strong></td>
<td><strong>5933</strong></td>
<td><strong>5921</strong></td>
<td><strong>1.02</strong></td>
<td><strong>[0.94, 1.11]</strong></td>
<td><strong>100.0%</strong></td>
</tr>
</tbody>
</table>

Chart 3 Forest plot. Effect of convalescent plasma use, Outcome: Mortality at 30 days, Randomized controlled studies. Subgroup analysis: Studies with high risk of bias and/or low antibody tidy vs low risk of bias and high antibody tidys.

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Risk Ratio</th>
<th>RR 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rob_HIGH</td>
<td>0.65</td>
<td>[0.29, 1.46]</td>
</tr>
<tr>
<td>Li Ly col 2020</td>
<td>0.03</td>
<td>[0.00, 1.41]</td>
</tr>
<tr>
<td>CONCOVID 2020</td>
<td>0.05</td>
<td>[0.22, 1.34]</td>
</tr>
<tr>
<td>Placid-Trial 2020</td>
<td>0.94</td>
<td>[0.80, 1.17]</td>
</tr>
<tr>
<td>ILBS 02 COVID-19 2020</td>
<td>3.21</td>
<td>[0.36, 2.40]</td>
</tr>
<tr>
<td>PICP 19 Ray y col 2020</td>
<td>0.50</td>
<td>[0.05, 5.08]</td>
</tr>
<tr>
<td><strong>Random effects model</strong></td>
<td><strong>0.79</strong></td>
<td><strong>[0.67, 1.10]</strong></td>
</tr>
</tbody>
</table>

| Rob_LOW           | 0.96       | [0.50, 1.83] |
| Plasma AR 2020    | 0.50       | [0.09, 2.65] |
| Libster y col (INFANT) 2021 | 1.04 | [0.06, 1.13] |
| Recovery plasma 2020 | 1.04 | [0.93, 1.17] |
| **Random effects model** | **1.04** | **[0.93, 1.17]** |

Fixed effects (plural) model

| Prediction interval |
|---------------------|-----------|
| 1.03 [0.98; 1.08]   | 0.01 [0.94; 1.12] |
Convalescent plasma could produce a marginal increase in admission to mechanical ventilation, RR 1.17 (95% CI 0.80 to 1.70); RD 2% (95% CI -2% to 8%); Low certainty ◊◊. see Graph 4 Forest plot

Graph 4 Forest plot. Effect of the use of convalescent plasma, Outcome: Admission to mechanical ventilatory assistance (MVA), Subgroup Randomized controlled studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Experimental Events</th>
<th>Control Events</th>
<th>Risk Ratio</th>
<th>RR</th>
<th>95% CI</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma-AR 2020</td>
<td>61</td>
<td>228</td>
<td>1.17</td>
<td>1.17</td>
<td>[0.78; 1.77]</td>
<td>55.6%</td>
</tr>
<tr>
<td>Li L y col 2020</td>
<td>14</td>
<td>51</td>
<td>1.25</td>
<td>1.25</td>
<td>[0.63; 2.48]</td>
<td>19.8%</td>
</tr>
<tr>
<td>ConfIces 2020</td>
<td>0</td>
<td>36</td>
<td>0.02</td>
<td>0.02</td>
<td>[0.00; 0.45]</td>
<td>0.2%</td>
</tr>
<tr>
<td>Placid Trial 2020</td>
<td>20</td>
<td>229</td>
<td>1.14</td>
<td>1.14</td>
<td>[0.62; 2.10]</td>
<td>25.6%</td>
</tr>
<tr>
<td>Random effects model</td>
<td>548</td>
<td>433</td>
<td>1.17</td>
<td>1.17</td>
<td>[0.80; 1.70]</td>
<td>100.0%</td>
</tr>
</tbody>
</table>

Prediction interval
Heterogeneity: I² = 0%, τ² = 0, p = 0.57

Outcome serious adverse events

Convalescent plasma could produce a marginal increase in serious adverse events, RR 1.27 (95% CI 0.72 to 2.24); RD 1.4% (95% CI: -1.6% to 6.7%); Low certainty ◊◊

◯◯.


Outcome: serious adverse events
**Discussion**

Evidence from cohorts [21] [22] [23] [24] where convalescent plasma was openly infused to large numbers of people provides us with a large amount of data, but this evidence is nonetheless very low certainty.

One of the observations made on this type of observational study such as the one carried out by the Mayo Clinic [21] is the low occurrence of adverse events (transfusion-related volume overload 0.4%, transfusion-related acute pulmonary injury 0, 22% and severe transfusion allergic reaction 0.06%). However, given the clinical characteristics in the evolution of the coronavirus disease (sometimes clinical and imaging manifestations difficult to distinguish, for example, from a transfusion-related lung injury) and the lack of rigor in the reports of adverse events in this type of registry (or substantially less than that of a clinical trial) is that we prefer to prioritize the certainty of the evidence in adverse events occurring in clinical trials (see evidence profile).

In our study, we found that the use of convalescent plasma does not impact the mortality of patients with moderate to critical illness.

It could be associated in a borderline manner with an increase in admission to mechanical ventilation and in the incidence of serious adverse events. Regarding other less important outcomes such as time to clinical improvement, there is also uncertainty in the effect of the intervention. These statements are based on a low certainty of the evidence, due to the risk of bias in the included studies and unexplained heterogeneity. Subgroup analyzes performed for risk of bias and quality of the infused product (related to antibody concentration) could not explain this heterogeneity. We can hypothesize that the co-interventions, the severity of the patients included through the studies and the timing of the infusion could influence it.

**Conclusion**

The results of ten RCTs (randomized controlled trials) that evaluated the use of convalescent plasma in patients with COVID-19 did not show significant differences in the effect on mortality and the need for invasive mechanical ventilation. For some outcomes, the certainty in the evidence is still low and more information is needed from properly designed studies to be able to improve the certainty in the direction and magnitude of the effect.

One of the greatest difficulties with this and other interventions that are used in the treatment of Covid-19, is the form of registration of interventions of unproven efficacy or still without preclinical evidence or in phases I and II of research. This deficit of records, deficient records or not intended to provide reliable data, cause a significant delay in knowledge in this area.

Current evidence shows that the use of convalescent plasma has no effect on critical outcomes in patients with moderate or severe COVID-19. Its early use, in moderate high-risk patients with a
product with a very high antibody titer, based on its biological plausibility, has an uncertain benefit and is not feasible to implement, and could negatively impact the equity of the health system.

Financing sources
We do not have external sources of financing to carry out this study

References:


